Liquidia Corporation (NASDAQ:LQDA) Stock Rated "Hold" by Wall Street Brokerages

Key Points

• Analyst consensus on Liquidia is “Hold.” Of 11 analysts, five rate the stock a buy, one a strong buy, three a hold and two a sell; the average 12-month price target is $98.08.
• Liquidia reported 1842.1% year-over-year revenue growth to $171.68 million, though quarterly EPS of $0.74 narrowly missed the $0.76 consensus estimate. Shares opened at $68.43, compared with a 52-week range of $21.15 to $93.61.
• Insiders sold 622,519 shares worth approximately $48.1 million over the last quarter, while institutional investors and hedge funds own 64.54% of the stock.

Shares of Liquidia Corporation (NASDAQ:LQDA - Get Free Report) have earned an average recommendation of "Hold" from the eleven analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $98.08.

Several analysts recently commented on LQDA shares. BTIG Research raised their price target on shares of Liquidia from $109.00 to $111.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th. Raymond James Financial reissued a "strong-buy" rating and set a $106.00 target price on shares of Liquidia in a research report on Thursday, August 13th. HC Wainwright set a $36.00 price target on shares of Liquidia in a research report on Friday, July 24th. Royal Bank Of Canada set a $130.00 price target on shares of Liquidia in a report on Friday, July 24th. Finally, Wells Fargo & Company increased their target price on Liquidia from $62.00 to $108.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th.

Liquidia Stock Performance

Shares of LQDA stock opened at $68.43 on Monday. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $6.13 billion, a P/E ratio of 49.95 and a beta of 0.53. The stock has a 50-day simple moving average of $75.40 and a 200 day simple moving average of $61.90. Liquidia has a fifty-two week low of $21.15 and a fifty-two week high of $93.61.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). The company had revenue of $171.68 million for the quarter, compared to analysts' expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company's revenue for the quarter was up 1842.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.49) earnings per share. On average, sell-side analysts expect that Liquidia will post 2.57 earnings per share for the current fiscal year.

Insider Activity

In other Liquidia news, insider Rajeev Saggar sold 50,000 shares of the company's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the transaction, the insider owned 142,265 shares of the company's stock, valued at approximately $10,536,145.90. This represents a 26.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Raman Singh sold 8,468 shares of the firm's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $66.16, for a total transaction of $560,242.88. Following the completion of the transaction, the director directly owned 44,637 shares in the company, valued at approximately $2,953,183.92. The trade was a 15.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 622,519 shares of company stock worth $48,078,514. 25.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its stake in Liquidia by 63.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company's stock worth $2,199,000 after purchasing an additional 22,592 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Liquidia during the 2nd quarter worth about $29,694,000. Seven Fleet Capital Management LP lifted its position in shares of Liquidia by 25.2% in the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company's stock valued at $20,459,000 after buying an additional 51,727 shares during the last quarter. Handelsbanken Fonder AB bought a new position in Liquidia during the second quarter worth $1,993,000. Finally, WCG Wealth Advisors LLC boosted its holdings in shares of Liquidia by 98.2% during the 4th quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company's stock worth $1,877,000 after buying an additional 26,957 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia's lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.